Indication

Treatment of Duchenne muscular dystrophy resulting from a nonsense mutation in the dystrophin gene, in ambulatory patients aged 2 years and older.

Medicine details

Medicine name:
ataluren (Translarna)
SMC ID:
SMC2327
Pharmaceutical company
PTC Therapeutics
BNF chapter
Musculoskeletal and joint diseases
Publication due date:
12 April 2021
SMC meeting date:
02 March 2021
Patient group submission deadline:
01 February 2021